Radioimmunoassay for N-terminal probrain natriuretic peptide in human plasma

Schulz, Helene; Langvik, T. Å.; Sagen, Ellen Lund; Smith, Julie; Ahmadi, Nader; Hall, Christian

doi:10.1080/00365510151067947

Cited by 43 publications

(28 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immunoassays may nevertheless still detect the intact prohormone and therefore not reflect the actual bioactivity of the secreted peptides. In agreement with this suggestion, patients with congestive heart failure have increased plasma concentrations of immunoreactive N-terminal proBNP, and this immunoreactive material seems to also contain a polypeptide corresponding to the intact precursor (16,39,40 ). Thus, the congestion in heart failure patients may not be ameliorated by the secreted natriuretic peptides.…”

Section: Endocrine Paradox In Heart Failuresupporting

confidence: 59%

“…It is therefore important to realize that the preproBNP molecule does not exist in real life but is only as a theoretical concept. In contrast, proBNP is likely an existing small protein, the existence of which to date has been indicated by chromatographic studies and sequence-specific immunoassays (16,39,40 ). However, the actual precursor has not been identified on a molecular level, nor have the fragments thereof, apart from the C-terminal BNP-32 peptide itself (10 ).…”

Section: Structure Of Probnpmentioning

confidence: 99%

“…These fragments are commonly referred to as "N-terminal proBNP", but the molecular heterogeneity also includes the intact precursor, in particular in heart failure patients (16,39,40,75 ). Cardiac secretion of proBNP and its N-terminal fragments has been demonstrated by blood sampling from the coronary sinus (76,77 ).…”

Section: Probnp-derived Peptides In Plasmamentioning

confidence: 99%

See 2 more Smart Citations

Biochemistry of Pro-B-Type Natriuretic Peptide-Derived Peptides: The Endocrine Heart Revisited

2004

View full text Add to dashboard Cite

Background: Since the discovery of cardiac hormones almost 25 years ago, a vast amount of clinical research has identified the cardiac natriuretic peptides and their precursors as markers of heart failure. It even seems likely that the pro-B-type natriuretic peptide (proBNP)-derived peptides in plasma may become the most frequently measured peptides in the daily diagnosis and control of therapy. In contrast, the biochemistry of the peptides has received less attention. Methods: Published data available on the National Library of Medicine (NLM) were used as the basis for the review. Outcome: This review shows that the present understanding of the biochemistry of peptides is far from complete. In particular, cellular synthesis, including posttranslational precursor maturation, is poorly understood. Moreover, elimination of the precursor fragments is unknown. Elucidation of the molecular heterogeneity of proBNP products will therefore contribute to the understanding of the endocrine heart and may also have important diagnostic consequences. Above all, the different proBNP-derived peptides may not always be equal markers of the same pathophysiologic processes. A different metabolism and peripheral elimination may also impose new and peptide-specific limitations for diagnostic use. Conclusions: It is necessary to focus more on the biology of the proBNP-derived peptides. In turn, new insight into the biochemistry could pave the way for more sensitive and disease-specific assays in the clinical setting.

show abstract

Section: Endocrine Paradox In Heart Failuresupporting

confidence: 59%

Section: Structure Of Probnpmentioning

confidence: 99%

See 1 more Smart Citation

Biochemistry of Pro-B-Type Natriuretic Peptide-Derived Peptides: The Endocrine Heart Revisited

2004

View full text Add to dashboard Cite

show abstract

“…NT-proBNP assays theoretically should show 100% cross-reactivity with proBNP. Furthermore, intact proBNP has been described in human plasma, and oligomerization probably occurs (11 ). Assays for BNP and NT-proBNP may differ in their susceptibility to analytical interferences.…”

Section: Information Requiredmentioning

confidence: 99%

Quality Specifications for B-Type Natriuretic Peptide Assays

et al. 2005

View full text Add to dashboard Cite

Background:The objective of this report is to improve the quality of immunochemical measurements of B-type natriuretic peptide (BNP) and its N-terminal propeptide (NT-proBNP). The recommendations proposed are intended for use by manufacturers of commercial assays, by clinical laboratories using those assays, by clinical trial groups and research investigators, and by regulatory agencies, such as the United States Food and Drug Administration. Methods: A group of cardiac biomarker experts reviewed and abstracted the scientific literature to provide recommendations pertaining to the quality specifications for BNP/NT-proBNP assays. Results: The evidence-based recommendations encourage manufacturers to endorse and consistently follow the proposed recommendations; encourage that all package inserts for BNP/NT-proBNP immunoassays include uniform information on assay design, preanalytical performance characteristics, analytical performance characteristics, and clinical performance; and encourage regulatory agencies to adopt a minimal and uniform set of criteria for manufacturers to provide when seeking clearance for new and/or improved assays. Conclusions: These recommendations address the use of BNP and NT-proBNP as cardiac biomarkers and not their physiologic and/or pathophysiologic relevance.

show abstract

“…High BNP levels in patients with chronic heart failure (CHF) often indicate poor ventricular function and a worse prognosis, but studies have shown that in some patients with severe chronic heart failure the plasma BNP level is normal [8,9]. In clinical practice, with quality laboratory resources, BNP has been introduced to diagnosis, prognosis and as a guide for treatment [10][11][12][13][14][15]. In this study, 57 patients with severe CHF seen at our hospital from December 2002 to October 2009, were studied, focusing on plasma levels of BNP, clinical features and prognosis.…”

mentioning

confidence: 99%

Clinical implications of normal B-type natriuretic peptide levels in patients with severe chronic heart failure

Gao

Guo

et al. 2014

Asian Biomedicine

View full text Add to dashboard Cite

Background: High plasma B-type natriuretic peptide (BNP) levels in patients with severe chronic heart failure (CHF) often indicate poor ventricular function and poor prognosis. However, in some such patients plasma BNP levels are normal. Objective: To investigate the clinical implications of BNP levels in patients with severe CHF. Methods: Fifty-seven patients with severe CHF were divided into group A (13 normal plasma BNP level) and 44 patients (high plasma BNP levels) group B. Diuretics, angiotensin-converting enzyme inhibitors (or angiotensin II receptor antagonist, e.g., metoprolol) and digitalis were used as conventional treatment. The clinical characteristics of all patients in two groups were analyzed and compared. Results: At the first admission, left ventricular end diastolic diameter in group B was significantly lower than group A (p < 0.05), and the plasma BNP level in group B was significantly higher than group A (p < 0.05). When metoprolol was used, 6 and 5 patients in group A and B could not tolerate the initial dose. In other cases using metoprolol at average maximum tolerance dose of metoprolol 12.5 6.25 and 24.20 11.22 mg/day in group A and B, respectively, there was a significant difference between them (p < 0.05). There were no significant differences in plasma BNP levels between two groups during stable period. The plasma BNP level in group B during acute worsening stage was significantly higher than in the remission stage (962.73 165.00 ng/L vs 876.24 167.70 ng/L, p < 0.05). However, there was no significant difference between group A (74.03 11.18 ng/L) and group B (71.38 11.68 ng/L) (p > 0.05). The mobility of group A was higher than group B (11/12 vs 6/44, p < 0.05). Logistic regression analysis showed that, the plasma BNP level was the independent risk factor for predicting cardiac death (regression coefficient, 3.817; OR, 45.488; 95% CI, 5.322"388.791). Conclusion: In patients with severe CHF, normal plasma BNP level suggests depletion of BNP secretion and further deterioration of cardiac function, indicating a poor prognosis.

show abstract

Radioimmunoassay for N-terminal probrain natriuretic peptide in human plasma

Cited by 43 publications

References 29 publications

Biochemistry of Pro-B-Type Natriuretic Peptide-Derived Peptides: The Endocrine Heart Revisited

Biochemistry of Pro-B-Type Natriuretic Peptide-Derived Peptides: The Endocrine Heart Revisited

Quality Specifications for B-Type Natriuretic Peptide Assays

Clinical implications of normal B-type natriuretic peptide levels in patients with severe chronic heart failure

Contact Info

Product

Resources

About